Sorbonne Department, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), THERAVIR team, Paris, France.
Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana.
J Med Virol. 2020 Feb;92(2):241-250. doi: 10.1002/jmv.25600. Epub 2019 Oct 20.
Active infections of human herpesvirus 6B (HHV-6B) are frequent in immunocompromised recipients after transplantation. Nevertheless, they need to be distinguished from latent inherited chromosomally integrated genomes (iciHHV-6) present in about 1% of the population to avoid unnecessary administration of toxic antivirals.
A 5-year-old child presented with acute liver allograft rejection associated with HHV-6 DNA in plasma, which led to an unfavorable outcome. We investigated the possibility of HHV-6 infection derived from an iciHHV-6 present in the donor's liver using molecular and histopathology studies in various tissues, including quantification of HHV-6 DNA, genotyping, sequencing for antiviral resistance genes, relative quantification of viral transcripts, and detection of gB and gH viral proteins.
The presence of iciHHV-6B was evidenced in the donor with signs of reactivation in the gallbladder and transplanted liver (detection of HHV-6B mRNA and late proteins). This localized expression could have played a role in liver rejection. Low viral loads in the recipient's plasma, with identical partial U39 sequences, were in favor of viral DNA released from the transplanted liver rather than a systemic infection.
Determination of iciHHV-6 status before transplantation should be considered to guide clinical decisions, such as antiviral prophylaxis, viral load monitoring, and antiviral therapy.
在移植后免疫功能低下的受者中,人类疱疹病毒 6B(HHV-6B)的活动性感染很常见。然而,为了避免不必要地使用有毒的抗病毒药物,需要将其与人群中约 1%存在的潜伏性染色体整合基因组(iciHHV-6)区分开来。
一名 5 岁儿童因急性肝移植排斥反应合并血浆中 HHV-6 DNA 而就诊,导致预后不良。我们通过对供体肝脏的各种组织(包括定量检测 HHV-6 DNA、基因分型、抗病毒耐药基因测序、病毒转录物相对定量和检测 gB 和 gH 病毒蛋白)进行分子和组织病理学研究,调查了源自供体肝脏中存在的 iciHHV-6 的 HHV-6 感染的可能性。
在供体中发现了 iciHHV-6B 的存在,并伴有胆囊和移植肝的再激活迹象(检测到 HHV-6B mRNA 和晚期蛋白)。这种局部表达可能在肝排斥中起作用。受者血浆中病毒载量较低,部分 U39 序列相同,提示病毒 DNA 来自移植肝而非全身感染。
在移植前应考虑确定 iciHHV-6 状态,以指导临床决策,如抗病毒预防、病毒载量监测和抗病毒治疗。